Dr. Ronald Rosenburg is Head of Clinical Development US. In his role, Dr. Rosenburg provides scientific oversight and medical risk-benefit analysis for the clinical development programs. He provides leadership for scientific and operational staff and ensures that the US site optimally supports the global development of compounds.
Prior to the start of his interational assignment at Grünenthal USA in January 2016, Dr. Rosenburg worked at our Headquarters in Aachen, Germany since 2012. He started as an International Clinical Lead before he took over the responsibility of Head of Clinical Development Strategy in 2014. In 2015, Dr. Rosenburg became a Senior International Clinical Lead, developing and executing the strategy for a compound and overseeing the medical aspect of clinical development activities.
Before joining Grünenthal, Dr. Rosenburg was an International Project Leader at Boehringer Ingelheim and held several positions at Sanofi-Aventis in Frankfurt, Germany.
Dr. Rosenburg completed his medical degree and studies at the Academy of Medical Enhancement and Moscow State Medical Institute.